About G-rich sequence factor 1
G-rich sequence factor 1 (GRSF1) is a protein
from Homo sapiens identified by UniProt accession
Q12849, 480 residues long.
MolForge cross-references it against 0 known binders and
46 disease associations.
Target properties
| Protein name | G-rich sequence factor 1 |
| UniProt accession | Q12849 |
| Gene | GRSF1 |
| Organism | Homo sapiens |
| Length | 480 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (46)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.51
- influenza · score 0.37
- clear cell renal carcinoma · score 0.27
- mean reticulocyte volume · score 0.19
- mean corpuscular volume · score 0.19
- Red cell distribution width · score 0.17
- mean corpuscular hemoglobin concentration · score 0.16
- type 2 diabetes mellitus · score 0.08
- lung adenocarcinoma · score 0.07
- hepatocellular carcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q12849-F1 | alphafold | PREDICTED | 65.54 | — |
Amino-acid sequence (480 residues)
MAGTRWVLGA LLRGCGCNCS SCRRTGAACL PFYSAAGSIP SGVSGRRRLL LLLGAAAAAA SQTRGLQTGP VPPGRLAGPP AVATSAAAAA AASYSALRAS LLPQSLAAAA AVPTRSYSQE SKTTYLEDLP PPPEYELAPS KLEEEVDDVF LIRAQGLPWS CTMEDVLNFF SDCRIRNGEN GIHFLLNRDG KRRGDALIEM ESEQDVQKAL EKHRMYMGQR YVEVYEINNE DVDALMKSLQ VKSSPVVNDG VVRLRGLPYS CNEKDIVDFF AGLNIVDITF VMDYRGRRKT GEAYVQFEEP EMANQALLKH REEIGNRYIE IFPSRRNEVR THVGSYKGKK IASFPTAKYI TEPEMVFEEH EVNEDIQPMT AFESEKEIEL PKEVPEKLPE AADFGTTSSL HFVHMRGLPF QANAQDIINF FAPLKPVRIT MEYSSSGKAT GEADVHFETH EDAVAAMLKD RSHVHHRYIE LFLNSCPKGK
Explore G-rich sequence factor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets